Fibrodysplasia Ossificans Progressiva (FOP) is a disorder in which muscle tissue and connective tissue like tendons and ligaments are replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone), which constrains movement.
FOP becomes apparent early in childhood. Infants are usually born with short, malformed big toes. About half of people with the disease also have malformed thumbs. Bone overgrowth tends to commence in the neck and shoulders, causing periodic bouts of painful inflammation. A low-grade fever sometimes accompanies this.
Fibrodysplasia Ossificans Progressiva Market
The market size of Fibrodysplasia Ossificans Progressiva in 7MM in 2017 was 1.76 USD Million
What are the Fibrodysplasia Ossificans Progressiva Market Drivers?
- Increase in the Research and Development Activity
- Upcoming Launches and Approval
- Awareness
What are the Fibrodysplasia Ossificans Progressiva Market Barriers?
- Fewer Patients
- Diagnosis Paradigm
- High Cost of Emerging Therapies
What are the Fibrodysplasia Ossificans Progressiva Emerging Drugs?
The emerging drugs of the Fibrodysplasia Ossificans Progressiva market are
- Palovarotene
- Garetosmab (REGN2477)
- BLU-782
- INCB00928
- Saracatinib (AZD0530 Difumarate)
- TAK 165
- And many others.
What are the Fibrodysplasia Ossificans Progressiva Key Players?
The key players in the Fibrodysplasia Ossificans Progressiva market are
- Ipsen
- Regeneron Pharmaceuticals
- Incyte Corporation
- VU University Medical Center (Collaborator: AstraZeneca)
- Kyoto University (Collaborator: Takeda)
- And many others.
What is C3G Treatment?
Complement 3 Glomerulopathy (C3G) is a group of rare kidneys diseases that are driven by dysregulation of the complement cascade. It is a type of glomerular disease, which is characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a major amount of immunoglobulin and without deposition of C1q and C4.
The term C3G covers the dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) that are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when seen under a microscope. People with DDD generally present at a younger age (childhood or adolescence) as compared to people with C3GN (adulthood).
Complement 3 Glomerulopathy Market
The market size of C3G in 7MM in 2017 was USD 40.6 Million
What are the Complement 3 Glomerulopathy Market Drivers?
- Intermediate Pipeline Activity
- Increase in Awareness
- The advent of Biomarkers in Near Future
What are the Complement 3 Glomerulopathy Market Barriers?
- Hurdles in Clinical Trial Settings
- Drawbacks of Renal Replacement Therapy
- Prone to Recurrence
- The Dominance of off-label Therapies
What are the Complement 3 Glomerulopathy Emerging Drugs?
The emerging drugs of the Complement 3 Glomerulopathy market are
- Danicopan (ACH-4471/ALXN2040)
- Narsoplimab (OMS721)
- Pegcetacoplan (APL-2)
- LNP023 (TBD)
- And many others.
What are the Complement 3 Glomerulopathy Key Players?
The key players in the Complement 3 Glomerulopathy market are
- Alexion Pharmaceuticals
- Omeros Corporation
- Apellis Pharmaceuticals
- Novartis Pharmaceuticals
- And many others.
Bipolar Disorder, formerly known as manic depressive illness or manic depression, is a mental disorder that is characterized by wide mood swings from manic to depressed. In depressive episodes (bipolar depression), the patient might feel sad, indifferent, or hopeless, combined with a shallow activity level.
The symptoms of bipolar depression are feeling sad or anxious; restless; trouble focusing or making decisions; trouble falling asleep, waking up too early, or sleeping too much; lack of interest; feeling hopeless or worthless, or thinking about death or suicide; unable to do even simple things, and talking very slowly.
The market size of Bipolar Depression in 7MM in 2017 was USD 762.83 million.
What are the Bipolar Depression Market Drivers?
- Novel insights into disease
- Improvement in treatment over the years
- Increasing adherence to treatment
- Increase in awareness and advancements in the technology
What are the Bipolar Depression Market Barriers?
- Delay in diagnosis
- Unrecognized and inappropriate treatment
- Neglects of quality of life, burden, and economic issues
- Unsatisfactory design of randomized controlled trials
- Lack of Knowledge to differentiate between unipolar and bipolar depression
What is the Bipolar Depression Emerging Drugs?
The emerging drugs of the Bipolar Depression market are
- Abilify (Aripiprazole)
- Lumateperone/ITI-007
- NRX-100/NRX-101
- Psilocybin
- Zuranolone (SAGE-217)
- SEP-4199
- ILT101
- Falkieri (Esketamine DPI)
- And many others.
What are the Bipolar Depression Key Players?
The key players in the Bipolar Depression market are
- Otsuka Pharmaceutical
- Intra-cellular Therapies
- NeuroRx
- COMPASS Pathways
- Sage Therapeutics
- Sunovion/Sumitomo Dainippon Pharma
- Iltoo Pharma
- Celon Pharma
- And many others.
Source: - Infographic Bipolar Disorder